Literature DB >> 29475924

Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases.

Dirk Rades1,2, Oliver Blanck3, Mai Trong Khoa2,4, Pham VAN Thai4, Nguyen Quang Hung4, Liesa Dziggel5, Steven E Schild6.   

Abstract

BACKGROUND/AIM: We developed a scoring system to predict 1-year survival after radiosurgery for 1-3 brain metastases. This study aimed to validate this system. PATIENTS AND METHODS: Seventy-six new patients were included in this validation study. Like in the original scoring-system, three factors (age, performance status, extra-cranial metastases) were used. For each factor, 1-year survival rates in % were divided by 10, and the three scoring-points were added for each patient.
RESULTS: Patient's scores were 10, 11, 13, 14, 16 or 17 points with 1-year survival rates ranging between 31% and 80%. Two groups, 10-14 and 16-17 points were formed. In the 14-16 points group, 1-year survival was 47% (versus 33% in the preceding study, p=0.060). In the 16-17 points group, 1-year survival rates were 75% versus 77% (p=0.79).
CONCLUSION: In the more favorable group, the scoring-system was very reproducible. In the less favorable group, the difference was larger, but also not signficant. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Radiosurgery; brain metastases; fractionated stereotactic radiotherapy; scoring-system; survival; validation

Mesh:

Year:  2018        PMID: 29475924      PMCID: PMC5905209          DOI: 10.21873/invivo.11249

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  22 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.

Authors:  Qiaowei He; Xizhuang Bi; Chao Ren; Yong Wang; Peng Zou; Hongtao Zhang; Nan Chi; Chunming Xiu; Yunbo Wang; Rongjie Tao
Journal:  Anticancer Res       Date:  2017-08       Impact factor: 2.480

Review 3.  Clinical Factors Asssociated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer.

Authors:  Liesa Dziggel; Steven E Schild; Theo Veninga; Amira Bajrovic; Dirk Rades
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

4.  A new tool to predict survival after radiosurgery alone for newly diagnosed cerebral metastases.

Authors:  Dirk Rades; Stefan Huttenlocher; Liesa Dziggel; Oliver Blanck; Dagmar Hornung; Khoa Trong Mai; Trang Thuy Ngo; Thai Van Pham; Steven Schild
Journal:  Asian Pac J Cancer Prev       Date:  2015

5.  Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: stereotactic radiosurgery versus surgical resection.

Authors:  Duong Anh Vuong; Dirk Rades; Albertus T C van Eck; Gerhard A Horstmann; Reinhard Busse
Journal:  Clin Neurol Neurosurg       Date:  2012-06-16       Impact factor: 1.876

6.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Authors:  Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher
Journal:  JAMA       Date:  2016-07-26       Impact factor: 56.272

7.  Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer.

Authors:  Liesa Dziggel; Markus Dahlke; Stefan Janssen; Dagmar Hornung; Oliver Blanck; Mai Trong Khoa; Steven E Schild; Dirk Rades
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

8.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

9.  Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

10.  Radiosurgery alone versus radiosurgery plus whole-brain irradiation for very few cerebral metastases from lung cancer.

Authors:  Dirk Rades; Stefan Huttenlocher; Dagmar Hornung; Oliver Blanck; Steven E Schild
Journal:  BMC Cancer       Date:  2014-12-11       Impact factor: 4.430

View more
  6 in total

1.  Survival After Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) for Cerebral Metastases in the Elderly.

Authors:  Dirk Rades; Trang Nguyen; Oliver Blanck; Steven E Schild
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement.

Authors:  Carsten Nieder; Astrid Dalhaug; Bård Mannsåker
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

3.  A Novel Score Combining Magnetic Resonance Spectroscopy Parameters and Systemic Immune-Inflammation Index Improves Prognosis Prediction in Non-Small Cell Lung Cancer Patients With Brain Metastases After Stereotactic Radiotherapy.

Authors:  Dong Guo; Jiafeng Liu; Yanping Li; Qingqing Chen; Yunzheng Zhao; Xinwei Guo; Shuchai Zhu; Shengjun Ji
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

4.  Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy.

Authors:  Jaspar Witteler; Troels W Kjaer; Soeren Tvilsted; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

5.  External Validation of the LabBM Score in Patients With Brain Metastases.

Authors:  Carsten Nieder; Astrid Dalhaug; Adam Pawinski
Journal:  J Clin Med Res       Date:  2019-04-14

6.  LabBM Score and Extracranial Score As New Tools for Predicting Survival in Patients with Brain Metastases Treated with Focal Radiotherapy.

Authors:  Carsten Nieder; Rosalba Yobuta; Bård Mannsåker
Journal:  Cureus       Date:  2020-04-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.